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ABSTRACT
Objectives: To evaluate the suggested association
between antidopaminergic drugs and acute
pancreatitis.
Design: A large population-based nested caseecontrol
study.
Setting: Swedish nationwide study from 2006 to
2008.
Participants: The Patient Register was used to
identify 6161 cases of acute pancreatitis. The 61637
control subjects were randomly selected from the
Register of the Total Population by frequency-based
density sampling, matched for age, sex and calendar
year.
Exposure: Exposure data were extracted from the
Prescribed Drug Register. Antidopaminergic drugs
were grouped into antiemetic/anxiolytic and other
antipsychotics. Current use of antidopaminergic drugs
was deﬁned as ﬁlling a prescription 1e114 days
before index date, while previous use was 115 days to
3.5 years before index date.
Main outcome measures: Cases were deﬁned as
being diagnosed as having acute pancreatitis. ORs and
95% CIs were calculated using unconditional logistic
regression.
Results: The unadjusted OR indicated an increased
risk of acute pancreatitis among current users of
antiemetic/anxiolytics (OR 1.9, 95% CI 1.4 to 2.6), but
not in the multivariable model adjusting for alcohol-
related comorbidity, chronic obstructive lung disease,
ischaemic heart disease, obesity, diabetes, opioid use,
gallstone disease, educational level, marital status and
number of concomitant medications (OR 0.9, 95% CI
0.6 to 1.2). Similarly, among current users of other
antipsychotics, the unadjusted OR was 1.4 (95% CI 1.1
to 1.6), while the adjusted OR was 0.8 (95% CI 0.6 to
0.9). Results regarding previous use of
antidopaminergic drugs followed a similar risk pattern
as for current use.
Conclusions: The lack of association between
antidopaminergic drugs and acute pancreatitis
after adjustment for confounding factors in this study
suggests that the previously reported positive
associations might be explained by confounding.
INTRODUCTION
The incidence of acute pancreatitis is
increasing for reasons that are not well
understood.
1 The main risk factors, that is,
gallstones and excessive alcohol consump-
tion, are present in approximately 40% and
30% of cases, respectively, while about 25%
are of idiopathic (unknown) origin.
1 There
have been several case reports of acute
pancreatitis during use of antidopaminergic
medication.
2e18 Typically, the reported cases
had initiated their medication within the
6 months before the onset of acute pancrea-
titis
5791 21 5 e19 and had recovered after
withdrawing or switching antidopaminergic
drug.
51 11 21 5 e19 Some case reports have
also reported recurrent pancreatitis after
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ARTICLE SUMMARY
Article focus
- Case reports and case series have suggested
a link between use of antidopaminergic drugs
and acute pancreatitis.
- The aim of this study was to clarify the
relationship between use of antidopaminergic
drugs and the risk of acute pancreatitis.
- We hypothesised that antidopaminergic drug use
increases the risk of acute pancreatitis.
Key messages
- Our paper suggests that there is no association
between antidopaminergic drug treatment and
acute pancreatitis when adjusting for potentially
confounding variables.
- Furthermore, our ﬁndings suggest that the
previously reported positive association might
be explained by confounding.
Strengths and limitations of this study
- Major strengths of the study are the population-
based design, utilising a nationwide register,
counteracting recall and selection bias.
- Limitations include the relatively small number of
acute pancreatitis cases during antidopaminergic
exposure, lack of information on medication
treatment during hospitalisation and lack of
information about adherence to the prescribed
medications.
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Open Access Researchrechallenge of the suspected drug.
81 8Two possible
biological mechanisms have been suggested. First,
a hypersensitivity reaction might be occurring, an
explanation that ﬁts well with the observation that some
cases have experienced recurrent pancreatitis at a much
lower dose and much earlier at rechallenge and is in line
with the well-described hypersensitivity reactions, mainly
for clozapine with subsequent agranulocytosis or
myocarditis.
18 20 Second, hypertriglyceridemia might be
induced by the antidopaminergic drug, resulting in an
accumulation of chylomicrons.
17 However, the sparse
epidemiological data available have not shown any clear
positive association between antidopaminergic medica-
tion and the risk of acute pancreatitis.
21 22 Larger
epidemiological studies elucidating this possible associ-
ation are warranted before any association can be
established or excluded. The aim of this study was
therefore to clarify the relationship between use of
antidopaminergic drugs and the risk of acute pancrea-
titis in a large and population-based study, including
adjustment for potential confounders. We hypothesised
that antidopaminergic drug use increases the risk of
acute pancreatitis.
METHODS
Study design
A Swedish nationwide population-based caseecontrol
study was performed in the period from 1 January 2006
to 31 December 2008. The source population was
deﬁned as all Swedish residents aged between 40 and
84 years. The Patient Register was used to identify cases
with a ﬁrst episode of acute pancreatitis. The Register of
the Total Population was used to randomly select control
subjects from the general population. Individual data on
drug exposure among cases and control subjects were
collected from the Prescribed Drug Register. Informa-
tion on the highest achieved formal educational level
was obtained from the Education Register. In order to
censor for person-time no longer at risk of being diag-
nosed as having acute pancreatitis in the Patient
Register, data regarding emigration and death were
obtained from the Register of the Total Population and
the Causes of Death Register, respectively. Additionally,
censoring for any cancer was conducted through the
Cancer Register. The unique personal identity number
assigned to all Swedish residents was used to link indi-
vidual information between the registers.
23 The study
has been approved by the Regional Ethical Review Board
in Stockholm.
Sources of data
The Patient Register comprises information on all inhos-
pital care and outpatient specialist care in Sweden,
including codes for diagnoses (according to the ‘Inter-
national Classiﬁcation of Diagnoses’ (ICD)) and surgical
procedures (according to the ‘Nordic Classiﬁcation of
Surgical Procedures’). It has complete nationwide
coverage of inpatient data since 1987 and complete
outpatient specialist care data since 2001.
24
The Prescribed Drug Register records all medications
dispensed to individual patients since 1 July 2005,
capturing the entire Swedish population of approxi-
mately 9 million inhabitants.
25 This register contains
data on drugs, including names of drug substances
according to the Anatomical Therapeutic Chemical
(ATC) classiﬁcation.
26 Additionally, it includes informa-
tion about amount, dosage and date of expenditure and
reimbursement, as well as patient data including age, sex
and place of residence. The register lacks information
regarding indication for treatment, over-the-counter
drugs and drugs administered at hospitals during inpa-
tient treatment.
The Cancer Register was set up in 1958, and since then
every clinician, pathologist and cytologist in Sweden has
been required to notify the National Board of Health
and Welfare of every person diagnosed as having a new
primary malignancy. The Cancer Register includes
primary malignancies and certain benign tumours and
precancerous lesions classiﬁed according to the ICD
system.
27
The Causes of Death Register contains information on the
dates and causes of all deaths of Swedish residents since
1952, with 100% coverage of death dates.
28
The Register of the Total Population contains individual
characteristics of all Swedish residents since 1968 (100%
coverage), including sex, age, country of birth, marital
status and place of residence.
29
The Education Register was established by Statistics
Sweden in 1985 and is annually updated with informa-
tion on the highest formal education attained by each
individual, from elementary to post-graduate level.
30
Case and control identiﬁcation
Cases were deﬁned as individuals in the study cohort
with a ﬁrst time registered discharge diagnosis in the
Patient Register of acute pancreatitis between 2006 and
2008. The code K85 in the 10th version of the ICD
represented acute pancreatitis. Control subjects were
randomly selected according to the principle of
frequency-based density sampling, matched for age, sex
and calendar year. Exposure was considered in relation
to an index date assigned to each case and control
participant. For case subjects, the index date was set to
the date of admission for acute pancreatitis. For control
subjects, the index date was a randomly assigned date
within the study period. All potential case and control
subjects with a previous cancer (apart from non-mela-
noma cancers of the skin) or any pancreatic disease
(deﬁned by the diagnosis codes K85, K86, K87 (ICD-10)
and 577 (ICD-9)) recorded in the Patient Register
before the study started were excluded.
Exposure to antidopaminergic drugs
Dispensed drug prescriptions of antidopaminergic
drugs were identiﬁed by their speciﬁc ATC code (N05A)
in the Prescribed Drug Register. Only exposure prior to
the index date was considered. As drugs for longer term
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Antidopaminergic drugs and acute pancreatitisuse typically are dispensed for 3-month periods in
Sweden, we assumed that a prescription normally
comprised 100 days of drug use and added a margin of
14 days. Thus, a single prescription of antidopaminergic
drugs was assumed to last 114 days. Antidopaminergic
drug use was deﬁned as ‘current’, ‘recent’, ‘past’ or
‘former’, if the drug had been dispensed 1e114 days,
115e180 days, 181e365 days or 1e3.5 years before the
index date, respectively. Previous use was categorised to
enable us to study short-term effects and better evaluate
potential confounding effects of concomitant diseases.
Depot formulations were recalculated to ﬁt the above
categorisation. The absence of any prescription for
antidopaminergic drugs was classiﬁed as ‘non-use’. Two
groups of antidopaminergic drugs were studied sepa-
rately: (1) antiemetic/anxiolytics, including dixyrazine,
levomepromazine, melperone and prochlorperazine,
and (2) other antipsychotics, including ﬂuphenazine,
perphenazine, ﬂupenthixole, thioridazine, chlorprom-
azine, haloperidol, pimozide, ziprasidone, aripiprazole,
quetiapine, risperidone, paliperidone, clozapine
and olanzapine. A separate analysis of the two most
metabolically adverse antipsychotic drugs, clozapine
and olanzapine, was also conducted. To facilitate
comparison with previous studies, we also performed
secondary analyses grouping the antidopaminergic
drugs into atypical/typical antipsychotics and subdi-
viding typical into high-, medium- and low-potency
antipsychotics. Finally, to maximise power, we made an
analysis including any antidopaminergic drug use in
one group.
Statistical analysis
The RR of acute pancreatitis was estimated by uncondi-
tional logistic regression, which was used to calculate
ORs with 95% CIs. Adjustments were made in three
models: (1) a crude model was based on the matching
variables only, that is, sex, age (in 5-year age groups) and
the three calendar years; (2) a multivariable model
added (a) history of excessive alcohol consumption or
disease related to alcohol, deﬁned by the diagnosis codes
E244, F10, G312, G621, G721, I426, K292, K70, O354
and T51 in ICD-10 or 291, 303, 305A, 357F, 425F, 535D,
571A, 571B, 571C, 571D and 980 in ICD-9, or use of
antialcohol drugs deﬁned by the ATC code N07BB and
(3) a full multivariable model further added (b) chronic
obstructive lung disease, deﬁned by the diagnosis codes
J41, J42, J42 and J44 in ICD-10 or 491, 492 and 496 in
ICD-9, (c) ischaemic heart disease, deﬁned by the diag-
nosis codes I20eI25 in ICD-10 or 410e413, 414A and
414W in ICD-9, (d) obesity, deﬁned by the diagnosis
codes E66 in ICD-10 or 278A in ICD-9 or antiobesity
drugs deﬁned by the ATC code A08A, (e) diabetes,
deﬁned by the diagnosis codes E10eE14 in ICD-10 or
250 in ICD-9 or antidiabetic medication, deﬁned by the
ATC code A10, (f) opioid drug use, deﬁned by the ATC
code N02A, (g) gallstone disease, deﬁned by the diag-
nosis codes 574, 575A or 575B in ICD-9 or K80 and K81
in ICD-10, (h) educational level (divided into three
categories of highest attained education: elementary
school, secondary school, university and one category for
missing data (2.3% among cases and 1.6% among
controls)), (i) marital status (categorised as married or
not) and (j) a comorbidity score based on number of
distinct medications. The comorbidity score was deﬁned
as the sum of unique 7-digit ATC codes dispensed during
the 6 months prior to the index date and was categorised
as 0e4, 5e9, 10e14 or $15 drugs. Presence of the listed
diseases or conditions was determined by a recorded
hospitalisation or outpatient visit according to the
Patient Register since 1987 or a dispensed prescription
between 1 July 2005 and the index date. In a subanalysis,
the study period was restricted to 2007 and 2008 to
account for the fact that the study participants,
depending on their index date, had different follow-up
times from the start of the Prescribed Drug Register on 1
July 2005. Hence, for some participants included
throughout the entire study period, we could assess drug
exposure only 1e180 days before the index date. In
addition, the association between antidopaminergic
medication and acute pancreatitis was studied among
those with and without a previous hospital record of
psychosis, deﬁned by the diagnosis codes F20eF29 in
ICD-10 or 295, 296, 297 and 298 in ICD-9. The SAS
statistical software package EG 4.2 (SAS Institute) was
used for the analyses.
RESULTS
Study participants
The study included 6161 cases of acute pancreatitis and
61637 control subjects. Characteristics of the study
participants are presented in table 1. The frequency-
based sampling produced a similar age and sex (and
calendar year) distribution among cases and control
subjects. Among the cases, 78 had used antiemetic/
anxiolytic antidopaminergic drugs and 194 had used
other antipsychotics. Current and previous use of anti-
emetic/anxiolytics, as well as other antipsychotics, was
more common among cases than controls (table 1). All
covariates presented in the Methods section were over-
represented among the case subjects compared with the
control participants. This was especially evident for
factors representing lifestyle. Diseases related to alcohol
overconsumption were, for example, four times more
common in cases than controls (table 1).
Antiemetic/anxiolytics and risk of acute pancreatitis
Table 2 presents the ORs for the association between
antiemetic/anxiolytics use and other antipsychotic
medication and the risk of developing acute pancreatitis.
The ORs in the crude model, adjusting for the matching
variables, indicated an increased risk among current
users of antiemetic/anxiolytics (OR¼1.9, 96% CI 1.4 to
2.6) as well as for each of the categories representing
previous use of antiemetic/anxiolytics (table 2). In the
multivariable model, adjusting for alcohol-related
comorbidity, the risk among current users of antiemetic/
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Antidopaminergic drugs and acute pancreatitisanxiolytics was attenuated (OR¼1.4, 95% CI 1.0 to 1.9),
and in the full multivariable model, no increased risk for
acute pancreatitis was observed for current use of anti-
emetic/anxiolytic (OR¼0.9, 95% CI 0.6 to 1.2).
Other antipsychotic medication and risk of acute
pancreatitis
Correspondingly, current use of other antipsychotics was
associated with an increased risk of acute pancreatitis in
the crude model (OR¼1.4, 95% CI 1.1 to 1.6). However,
this risk increase disappeared after adjusting for
confounding by alcohol-related comorbidity (OR¼1.1,
95% CI 0.9 to 1.4). Each of the categories representing
previous use of other antipsychotics showed a similar
decrease in the ORs from the crude model to the fully
adjusted model (table 2).
For current use of clozapine or olanzapine, the OR in
the crude model was 1.6 (95% CI 1.1 to 2.3) and
decreased to 0.9 (95% CI 0.6 to 1.4) in the full multi-
variable model.
Stratifying by sex did not reveal any major differences
between the sexes (data not shown). When stratifying by
age, the results for the group younger than 65 years were
similar to those of the main analysis, but among those
65 years and older, the OR for current use was close to
unity in both the crude and the fully adjusted model
(data not shown). Among participants younger than
65 years, the group with a previous history of alcohol
overconsumption had no increased risk of acute
pancreatitis associated with current use of other anti-
psychotics, in either the crude or the full multivariable
model (OR 0.8, 95% CI 0.5 to 1.3 and OR 0.8, 95% CI
0.5 to 1.2, respectively). However, participants without
such history of alcohol overconsumption rendered
similar results as in the main analysis (data not shown).
Individuals with a previous hospital record of psychosis
had no increased risk for current use of other antipsy-
chotics in the crude or full multivariable model (data
not shown). However, participants with a previous
hospital record of psychosis who had stopped other
antipsychotic medication within the last 3 months were
at an increased risk of acute pancreatitis after adjustment
in the multivariable model (OR 4.0 95% 1.4 to 11.2).
Stratifying by calendar year (2006 and 2007e2008)
rendered similar results as in the main analysis (data not
shown).
Analysing cumulative dose of antidopaminergic drugs
since start of the Drug Register in 1st July 2005 and risk
of acute pancreatitis yielded the highest OR for the
lowest quartiles of total amount of Daily Deﬁned Dose
(OR 2.0, 95% CI 1.58 to 2.51) and the lowest OR for the
10% with the highest amount of Daily Deﬁned Dose
(OR¼0.93, 95% CI 0.72 to 1.21) in the crude model.
Adjustment for alcohol-related diseases attenuated the
association for all categories of cumulative dose (data
not shown).
Within 114 days before being admitted for acute
pancreatitis, 1098 (18%) of cases were hospitalised for
other reasons at least once, within 60 days before and
30 days before the corresponding hospitalised cases were
850 (14%) and 608 (9.9%), respectively. The corre-
sponding ﬁgures for hospitalisation in a psychiatric ward
was 78 (1.3%), 43 (0.7%) and 26 (0.4%), respectively.
The median length of stay for somatic hospitalisations
was 4.3 and 3 days for the three time intervals, respec-
tively, and for psychiatric hospitalisations 4.3 and 2 days.
The secondary analyses of atypical antipsychotics and
three potency groups of typical antipsychotics showed
low or no risk increase except for former use of medium
potency antipsychotics and a non-signiﬁcant increased
Table 1 Characteristics of cases with acute pancreatitis
and frequency-matched population control subjects in
Sweden during the period 2006e2008
Cases Controls
Number (%) Number (%)
Total 6161 (100.0) 61637 (100.0)
Sex
Women 2774 (45.0) 27745 (45.0)
Men 3387 (55.0) 33892 (55.0)
Age group (years)
40e44 522 (8.5) 5226 (8.5)
45e49 533 (8.7) 5336 (8.7)
50e54 648 (10.5) 6480 (10.5)
55e59 749 (12.2) 7498 (12.2)
60e64 883 (14.3) 8830 (14.3)
65e69 776 (12.6) 7760 (12.6)
70e74 702 (11.4) 7019 (11.4)
75e79 689 (11.2) 6889 (11.2)
80e84 659 (10.7) 6599 (10.7)
Use of other antidopaminergic drugs*
No use 5967 (96.9) 60415 (98.0)
Current (0e114 days) 108 (1.8) 807 (1.3)
Recent (115e180 days) 14 (0.2) 79 (0.1)
Past (6e12 months) 21 (0.3) 129 (0.2)
Former (>12 months) 51 (0.8) 207 (0.3)
Use of antiemetic/anxiolytic antidopaminergic drugsy
No use 6083 (98.7) 61315 (99.5)
Current (0e114 days) 36 (0.6) 201 (0.3)
Recent (115e180 days) 10 (0.2) 22 (0.0)
Past (6e12 months) 13 (0.2) 40 (0.1)
Former (>12 months) 19 (0.3) 59 (0.1)
Alcohol-related diagnoses or drugs for alcoholismz
No 5565 (90.3) 60030 (97.4)
Yes 596 (9.7) 1607 (2.6)
Gallstone-related diagnosesx
No 5086 (82.6) 59102 (95.9)
Yes 1075 (17.4) 2535 (4.1)
Generic name for antidopaminergic drugs used time before index
date.
*Fluphenazine, perphenazine, ﬂupenthixole, thioridazine,
chlorpromazine, haloperidol, pimozide, ziprasidone, aripiprazole,
quetipaine, risperidone, paliperidone, clozapine and olanzapine.
yDixyrazine, levomepromazine, melperone and proklorperazine.
zInternational Classiﬁcation of disease ICD: E244, F10, G312,
G621, G721, I426, K292, K70, O354 or T51 in ICD-10 or 291, 303,
305A, 357F, 425F, 535D, 571A, 571B, 571C, 571D or 980 in ICD-9
or drugs used for treatment of alcohol addiction.
xInternational Classiﬁcation of disease ICD: K80 or K81 in ICD-10
or 574, 575A or 575B.
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Antidopaminergic drugs and acute pancreatitisrisk for recent use of low-potency antipsychotics
(supplemental tables I and II). Use of any anti-
dopaminergic drug was not associated with increased
risk of acute pancreatitis.
DISCUSSION
This population-based study found no association
between current use of antidopaminergic medication
and acute pancreatitis after adjustment for potential
confounding factors.
Among strengths of the study is the population-based
design, utilising a nationwide register, counteracting
recall and selection bias. Other advantages include the
large sample size, the complete nationwide coverage of
the exposure (antidopaminergic drugs) and the
outcome (acute pancreatitis) and the adjustment for
several potential confounding factors. Misclassiﬁcation
of the outcome in the Patient Register is a possible
concern, but the high validity of the diagnosis of acute
pancreatitis in this register has recently been shown by
our group to have a positive predictive value of 98%.
31
There are, however, also several weaknesses. We
regarded a dispensed prescription of antidopaminergic
drugs as an exposure, but there was no information on
whether the patients had actually taken their medica-
tion. This potential misclassiﬁcation of the exposure
would most likely be non-differential, that is, not asso-
ciated with risk for future acute pancreatitis and thus,
dilute the risk estimates towards null results. Addition-
ally, there was no information on drugs administered
during inhospital care and no information on indication
for treatment. This might lead to a misclassiﬁcation
resulting in some of the patients with probably the
highest doses of antidopaminergic drugs (being inpa-
tient treated) being classiﬁed as not having been
exposed to antidopaminergic drugs. However, as other
hospitalisations prior to index hospitalisation for acute
pancreatitis were not common and were of short dura-
tion, we consider this potential misclassiﬁcation negli-
gible. Moreover, detailed patient information is not
available in registers, particularly regarding some
potential confounding factors. It could, for instance, be
possible that substantial alcohol consumption, smoking
or obesity could not be captured with the variables
retrieved from the national registers. Nevertheless,
several potential confounding variables were adjusted
for, and the results clearly show that confounding by
these factors did occur and were seemingly sufﬁciently
adjusted for. There is no reason to believe that misclas-
siﬁcation of alcohol exposure would be a greater
concern among the controls than the cases.
Use of antidopaminergic drugs in our study was asso-
ciated with an increased risk of acute pancreatitis in the
crude models, but after adjustment for known risk
factors for acute pancreatitis, this association disap-
peared. The principal confounding effect seemed to
be through alcohol, as the major decrease of the
elevated risk of acute pancreatitis among users of
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Antidopaminergic drugs and acute pancreatitisantidopaminergic drugs was attenuated when adjusting
for alcohol-related diagnoses and drug treatments for
alcohol dependence. This confounding may be for two
different reasons. First, antidopaminergic drugs are
used as a non-addictive alternative to treat withdrawal,
agitation and anxiety among patients with alcohol
dependence.
32 Second, alcohol dependence is over-
represented among patients with severe mental illnesses,
where antidopaminergic drugs often are the ﬁrst-line
treatment.
33 Not all the increased risk disappeared after
adjusting for alcohol; instead, the effect entirely disap-
peared only after further adjustment for additional
known risk factors for acute pancreatitis, that is, chronic
medical conditions, sociodemographic factors, obesity
and gallstone-related diseases.
This study revealed no association between clozapine
and olanzapine and the risk of acute pancreatitis. These
two antipsychotic drugs are known to be particularly
obesogenic, diabetogenic and with high liability of
inducing lipid abnormalities.
34e36 Yet, other studies have
shown that obesity, as well as diabetes, might increase the
risk of acute pancreatitis.
37 38
Furthermore, in our study, patients with a previous
hospital record of psychosis who had stopped using
other antipsychotic medication within the previous
3 months had an increased risk of acute pancreatitis
which remained after full adjustment. One possible
explanation of this delay in the effect is that patients with
a psychotic disorder are more non-adherent to phar-
macotherapy when suffering from a comorbid alcohol
abuse disorder.
39 Thus, patients might have stopped
their antipsychotic medication following a period of
excessive alcohol intake, which subsequently may have
led to an acute pancreatitis.
Before the analyses, we chose to divide anti-
dopaminergic drugs into two groups according to the
main clinical usage pattern. The antidopaminergic drugs
in the group antiemetic/anxiolytics are typically used
intermittently and in lower doses than other groups of
antidopaminergic drugs. Notably, users of antiemetic/
anxiolytic had a higher crude risk of acute pancreatitis
than users of other antipsychotics in our study, although
they probably received lower total doses. However, one
might speculate that if the antidopaminergic drugs in
the antiemetic/anxiolytic group are used more often for
treatment of withdrawal and anxiety in the post-detoxi-
ﬁcation phase from alcohol, than other antipsychotics, it
would explain this discrepancy. Other studies have
chosen to divide antidopaminergic drugs into conven-
tional and atypical antipsychotics,
13 22 but the rationale
behind such categorisation has been criticised and
recently has been proposed to be abandoned due to the
great overall heterogeneity within these groups.
40
However, for the sake of comparison with a recent
Danish caseecontrol study,
22 we performed secondary
analyses with the same categorisation of the anti-
dopaminergic drugs. Former use of medium potency
antipsychotics was associated with increased risk of
pancreatitis, as was recent use of low-potency antipsy-
chotics, even though non-signiﬁcant. Nevertheless, none
of the other time exposure categories were associated
with a risk increase, and thus, it is possible that those two
observations are chance ﬁndings. However, an actual
effect cannot be entirely ruled out as similar results have
been found previously and the CIs in the present study
are relatively large. However, it is reassuring that, at least,
no ﬁndings in the current use group approached
signiﬁcance and that there was an inverse relationship
between cumulative DDD and risk of pancreatitis.
Nevertheless, studies with larger numbers of patients
exposed to these individual agents are needed to
conﬁrm our ﬁndings.
The case reports and case series indicating an associ-
ation between antidopaminergic drugs and acute
pancreatitis concerned the following compounds previ-
ously attributed as atypicals: clozapine,
2 10 13 18 olanza-
pine,
3481 1 e13 17 quetiapine,
71 6risperidone,
5691 3
aripiprazole and
15 ziprasidone
19 and reported on the
conventional antipsychotics haloperidol and chlor-
promazine.
13 14 However, relying simply on adverse
reaction reports would probably exaggerate the possible
risk of acute pancreatitis, as case reports have a limited
capability to establish causality between drug use and
disease outcome in the absence of re-exposure conﬁr-
mation. There are few epidemiological studies available.
A Swedish caseecontrol study observed an overall
increased risk for all phenothiazines.
21 However, it
included clomethiazole among the phenothiazines,
a hypnotic compound which has been one of the ﬁrst-
line treatments for alcohol withdrawal, and adjustments
for alcohol comorbidity were not made. A recent Danish
pharmacoepidemiological study found an increased
risk for acute pancreatitis among current users of
low-potency conventional antipsychotics (mainly levo-
mepromazine) even after having adjusted for alcohol-
related diagnoses, whereas former users of atypicals
displayed a decreased risk.
22 The contrasting ﬁndings to
our study can probably be attributed to different meth-
odology, where we might have reduced residual
confounding by alcohol more completely, but it might
still be present in the Danish study. This was accom-
plished in our study, as we used a much broader deﬁni-
tion and inclusion of alcohol-related diagnoses, and we
also included prescription of medications used to treat
alcohol dependence.
In conclusion, this large population-based study with
complete data on the exposures and outcome indicates
that use of antidopaminergic drugs is not associated with
any increased risk of acute pancreatitis after proper
adjustment for confounding by known risk factors for
pancreatitis. Therefore, any acute pancreatitis among
antidopaminergic-treated patients might not be attrib-
uted to the antidopaminergic pharmacotherapy per se
but instead to the classical risk factors of acute pancre-
atitis such as excessive alcohol intake, gallstones and
obesity.
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